Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: A case report

M. Berretta, F. Martellotta, C. Simonelli, F. Di Benedetto, N. De Ruvo, A. Drigo, A. Bearz, M. Spina, E. Zanet, S. Berretta, Umberto Tirelli

Research output: Contribution to journalArticle

Abstract

Recent data have shown the efficacy of cetuximab/Folfiri regimen in patients with chemotherapy-resistant metastatic colorectal cancer. In the literature there are no data about this treatment in HIV-positive patients with metastatic colorectal cancer. At the Aviano Cancer Center, we used the cetuximab/Folfiri regimen and concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. The patient experienced acceptable non-hematological toxicity, without any opportunistic infection and his HIV infection was kept under control. This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection.

Original languageEnglish
Pages (from-to)343-346
Number of pages4
JournalJournal of Chemotherapy
Volume19
Issue number3
Publication statusPublished - Jun 2007

Keywords

  • Cetuximab
  • Colorectal cancer
  • Folfiri
  • HAART
  • HIV

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: A case report'. Together they form a unique fingerprint.

  • Cite this

    Berretta, M., Martellotta, F., Simonelli, C., Di Benedetto, F., De Ruvo, N., Drigo, A., Bearz, A., Spina, M., Zanet, E., Berretta, S., & Tirelli, U. (2007). Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: A case report. Journal of Chemotherapy, 19(3), 343-346.